首次出版:最新修訂:March 2009交付方式:特快專遞(2-3天送達)
報告屬性:共94頁下載目錄 版權(quán)聲明
定購電話:0755-82571522、82571566、400-008-1522
24小時服務(wù)熱線:138 0270 8576 定制報告
版本 | 在線版 | 電子版+印刷版 | 在線報告庫(超1000份報告)全庫 |
---|---|---|---|
優(yōu)惠價 | RMB 6800 | RMB 7800 | RMB 9800 |
原價 | RMB 9600 | RMB 9800 | - |
聯(lián)系電話: 400 008 0586; 0755-82571568
微信掃碼:
1.EXECUTIVESUMMARY
·Overview
OverviewoftheBladderCancerTherapeuticsMarket
2.GLOSSARYOFTERMS
·ListofTerms
Abbreviations
3.MARKETOVERVIEW
·Introduction
DiseaseCharacteristics
Epidemiology
·MarketDefinitionsandSegmentation
Definitions
Segmentation
4.RESEARCHMETHODOLOGYATFROST&SULLIVAN
·ResearchObjectivesandScope
ResearchMethodology
5.INDUSTRYCHALLENGES
·ChallengesfortheBladderCancerMarket
ChallengesFacedbyPharmaceuticalCompanies
6.TOTALEUROPEANMARKETFORBLADDERCANCERTHERAPEUTICS
·OverviewandDefintions
Introduction
MarketDrivers
MarketRestraints
CurrentTherapeuticOptions-SuperficialBladderCancer
CurrentTherapeuticOptions-InvasiveBladderCancer
FutureTherapeuticApproaches
CurrentTreatmentGuidelines
MarketEngineeringMeasurementAnalysis
·CompetitiveAnalysis
ProfilesofKeyIndustryParticipants
MarketShareAnalysis
PipelineAnalysis
7.TOTALFORECASTSFORTHEEUROPEANBLADDERCANCERTHERAPEUTICSMARKET
·Forecasts
PatientForecastsandGeographicalTrends
MarketRevenueForecasts
8.PRICINGANDREIMBURSEMENTINEUROPE
·PricingandReimbursementIssues
PricingandReimbursement-CountryAnalysis
PricingandReimbursement
9.STRATEGICRECOMMENDATIONSFORTHEEUROPEANBLADDERCANCERTHERAPEUTICSMARKET
·MarketEngineeringRecommendations
StrategicRecommendations
10.DATABASEOFKEYINDUSTRYPARTICIPANTS
·KeyIndustryParticipants
KeyParticipantsintheBladderCancerTherapeuticsMarket
11.DECISIONSUPPORTDATABASES
·HabitualIndicators
PrevalenceofMaleSmokers
PrevalenceofFemaleSmokers
PrevalenceofSmokers
·HealthcareExpenditure
Expenditure
PerCapitaHealthcareExpenditure
·CancerIncidence
BladderCancerIncidenceinWesternEurope
BladderCancerIncidenceinSelectedEuropeanCountries
·CancerMortality
BladderCancerMortalityinWesternEurope
BladderCancerMortalityinSelectedEuropeanCountries
This Frost & Sullivan research service titled European Bladder Cancer Therapeutics Markets presents a concise analysis of the market that includes challenges, factors driving growth and the revenue forecasts from 2003 to 2013. The study identifies the competitive opportunities within the market as well as strategies to exploit these opportunities and overcome industry challenges. In this research, Frost & Sullivan' s expert analysts thoroughly examine the cytotoxic (chemotherapy therapies) and targeted therapies segments.
This analysis is available through our Pharmaceuticals & Biotechnology Growth Partnership Services programme. With this programme, clients receive industry-leading market research such as this, along with technical and econometric data and many interactive features including Analyst Inquiry Time and Client Councils.